2-丁基-6-甲基吡啶 | 5335-76-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-丁基-6-甲基吡啶
• 英文名称: 2-n-butyl-6-methylpyridine
• 英文别名: 2-butyl-6-methylpyridine；2-butyl-6-methyl-pyridine；6-Butyl-2-picoline；2-Methyl-6-butyl-pyridin；2-Butyl-6-methylpyridin
• CAS: 5335-76-2
• 化学式: C₁₀H₁₅N
• 分子量: 149.236
• InChiKey: CTIJGOMYLLUVIK-UHFFFAOYSA-N

物化性质

• LogP：
  3.130 (est)
• 保留指数：
  1485;1485

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-丁基-6-甲基吡啶 、 6-喹喔啉羰酰氯 在 正丁基锂 、 氯化二乙基铝 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.83h， 以45%的产率得到2-(6-n-butylpyridin-2-yl)-1-(quinoxalin-6-yl)ethanone
  参考文献：
  名称：

  Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-β type 1 receptor kinase inhibitors

  摘要：

  A series of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles (15a-1) have been synthesized and evaluated for their ALK5 inhibitory activity in cell-based luciferase reporter assays. Among them, 4-[5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-ylmethyl]benzenesulfonamide (15b) and 4-[5-(6-ethylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-ylmethyl]benzene-sulfonamide (15c) showed more than 90% inhibition at 0.5 mu M in a luciferase reporter assay using HaCaT cells transiently transfected with p3TP-luc reporter construct, but inhibited p38 alpha MAP kinase activity only 11 and 8% at a concentration of 10 mu M, respectively. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.03.024
• 作为产物：
  描述：

  碳酸甲丙酯 在 palladium-carbon 氢气 作用下， 以 乙酸乙酯 为溶剂， 生成 2-丁基-6-甲基吡啶
  参考文献：
  名称：

  Pyridine-substituted benzyl alcohols as leukotriene antagonists

  摘要：

  具有I式化学式的化合物是白三烯的拮抗剂。这些化合物可用作抗哮喘、抗过敏、抗炎和细胞保护剂。它们还可用于治疗心绞痛、脑血管痉挛、肾小球肾炎、肝炎、内毒素血症、葡萄膜炎和移植排斥反应。

  公开号：

  US05506227A1

文献信息

• PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

  公开号：US20200247815A1

  公开（公告）日：2020-08-06

  The present invention relates to pyrazolyl-containing tricyclic derivative, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as shown in the general formula (I), a preparation method therefor and a pharmaceutical composition containing the compound, and the use thereof as a protease such as ERK (MAPK) inhibitor in the treatment of cancers, bone diseases, inflammatory diseases, immunological diseases, nervous system diseases, metabolic diseases, respiratory diseases and heart diseases, wherein the definition of each substituent in the general formula (1) is the same as defined in the description.

  本发明涉及吡唑基含有的三环衍生物，其制备方法及其用途。具体而言，本发明涉及一种如通式(I)所示的化合物，其制备方法及含有该化合物的药物组合物，以及将其用作蛋白酶，如ERK（MAPK）抑制剂，用于治疗癌症、骨疾病、炎症性疾病、免疫疾病、神经系统疾病、代谢性疾病、呼吸系统疾病和心脏疾病，其中通式（1）中每个取代基的定义与描述中定义的相同。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Corkey Britton Kenneth

  公开号：US20120289493A1

  公开（公告）日：2012-11-15

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类为钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该化合物的结构由式I给出： 其中Q、R1、X1、X2、Y和R2如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• Synthesis of Pyridines and Pyrazines Using an Intramolecular Hydroamination-Based Reaction Sequence
  作者：Toni Rizk、Eric J.-F. Bilodeau、André M. Beauchemin

  DOI：10.1002/anie.200903922

  日期：2009.10.19

  A management issue! Various pyridines and pyrazines can be efficiently accessed from simple acyclic precursors using an intramolecular hydroamination/isomerization/aromatization sequence (see scheme). p‐Toluenesulfonic acid (2 mol %) is used to catalyze this novel alkyne annulation, in which the oxime group allows for a subsequent redox‐neutral aromatization step to occur.

  管理问题！可以使用分子内加氢胺化/异构化/芳构化序列（参见方案）从简单的无环前体有效地获得各种吡啶和吡嗪。对甲苯磺酸（2摩尔％）用于催化这种新型炔烃环化反应，其中肟基允许随后的氧化还原中性芳构化步骤发生。
• [EN] VIRAL POLYMERASE INHIBITORS<br/>[FR] INHIBITEURS DE POLYMÉRASE VIRALE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009076747A1

  公开（公告）日：2009-06-25

  Compounds of formula I: wherein X, R2, R3, R3a, R3b,R5 and R6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

  式I的化合物：其中X，R2，R3，R3a，R3b，R5和R6在此处定义，可用作乙型肝炎病毒NS5B聚合酶的抑制剂。
• Proteasome inhibitors and methods of using the same
  申请人：Bernardini Raffaella

  公开号：US20090075936A1

  公开（公告）日：2009-03-19

  The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity.

  本发明提供了硼酸化合物、硼酸酯及其组合物，可以调节细胞凋亡，例如通过抑制蛋白酶体活性。这些化合物和组合物可以用于诱导细胞凋亡的方法，并用于治疗癌症和其他直接或间接与蛋白酶体活性相关的疾病。